How Chronic Pain Rewires the Nervous System

Pain That Stays After the Injury Heals

Approximately 50 million American adults—about 20% of the adult population—experience chronic pain, defined as pain persisting for more than three months. Of those, roughly 19.6 million have high-impact chronic pain that limits daily activities, according to the CDC's 2019 National Health Interview Survey. The economic burden exceeds $560–635 billion annually in direct medical costs and lost productivity—more than the combined costs of cancer, heart disease, and diabetes. Yet chronic pain remains poorly understood by patients and undertreated by the medical system. The fundamental reason: chronic pain is not simply prolonged acute pain. It is a fundamentally different condition involving structural and functional changes to the nervous system itself.

Acute vs. Chronic Pain: A Biological Difference

Acute pain serves a vital biological function. A broken bone hurts because nociceptors—specialized pain receptors—detect tissue damage and send signals through A-delta and C nerve fibers to the spinal cord, where they synapse on neurons that relay signals to the brain. Pain drives protective behavior: you stop walking on the broken bone. It heals. The pain resolves. System working as designed.

Chronic pain breaks this straightforward signal chain. In chronic pain, the nervous system undergoes neuroplastic changes—lasting structural and functional reorganization—that cause pain to persist and amplify independently of ongoing tissue damage. The problem is no longer in the injured tissue. The problem is in the nervous system itself.

Central Sensitization: The Core Mechanism

Central sensitization is the process by which the central nervous system—the spinal cord and brain—becomes hypersensitive to pain signals. Following sustained nociceptive input (prolonged pain signaling from injury), spinal cord neurons undergo changes that lower their activation threshold and amplify their response to incoming signals.

The molecular mechanisms include:

• NMDA receptor activation: Sustained C-fiber input releases glutamate and substance P at spinal synapses, activating NMDA receptors that had been inactive. NMDA activation triggers calcium influx into postsynaptic neurons, initiating intracellular signaling cascades that strengthen synaptic transmission and lower firing thresholds.
• Synaptic potentiation: Long-term potentiation (LTP)—the same mechanism underlying memory formation—occurs at spinal pain synapses, making pain pathways more easily activated.
• Expanded receptive fields: Sensitized spinal neurons begin responding to signals from larger areas of the body, explaining why fibromyalgia patients experience widespread pain from a localized initial injury.

The Wind-Up Phenomenon

Wind-up is the progressive increase in action potential output from spinal neurons in response to repeated, identical C-fiber stimuli. If you apply the same modest painful stimulus repeatedly, a sensitized nervous system produces increasing pain responses to each application—not decreasing responses as the body adapts. Wind-up is the experimental model that demonstrates how chronic pain amplification works in real time.

Clinically, wind-up manifests as allodynia (pain from stimuli that don't normally cause pain—a light touch, clothing against skin) and hyperalgesia (exaggerated pain from stimuli that normally cause mild pain). Fibromyalgia patients demonstrate both: pressure applied to tender points that would be insignificant to most people produces severe pain.

Glial Cell Activation: The Immune System's Role in Chronic Pain

Microglia and astrocytes—the immune cells of the central nervous system—were once thought to be passive support cells. Research since the early 2000s has revealed that they actively shape pain processing and play a central role in chronic pain development.

Following nerve injury or sustained pain signaling, microglia in the spinal cord become activated, shifting from a resting surveillance state to an activated inflammatory state. They release pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and brain-derived neurotrophic factor (BDNF), which further sensitize pain neurons by altering inhibitory signaling. Astrocytes contribute by downregulating glutamate transporters, allowing glutamate to accumulate at synapses and maintain excitatory drive.

• Activated microglia can be visualized using PET imaging with ligands for translocator protein (TSPO), a marker of neuroinflammation—studies show elevated microglial activation in fibromyalgia, complex regional pain syndrome, and central sensitization disorders
• Sex differences in microglial signaling may partly explain why women are more susceptible to chronic pain conditions—female rodents use BDNF-dependent microglial mechanisms while males use different pathways
• Anti-inflammatory approaches targeting glial activation are an active research area for chronic pain treatment

Fibromyalgia: Central Sensitization as a Disease

Fibromyalgia is now classified by the American College of Rheumatology as a central sensitization disorder rather than a musculoskeletal condition. Patients experience widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties ("fibro fog") despite normal blood tests, imaging, and joint examinations.

Functional MRI studies show that fibromyalgia patients have measurably different default mode network activity and abnormal connectivity between pain processing regions. PET studies show altered opioid receptor binding patterns. The pain is real, neurologically verifiable, and represents a fundamentally altered pain processing system—not exaggeration or psychological fabrication.

Fibromyalgia affects an estimated 4 million U.S. adults, approximately 80% of whom are female. FDA-approved treatments include duloxetine (Cymbalta), milnacipran (Savella), and pregabalin (Lyrica)—all of which modulate central pain processing rather than addressing peripheral tissue damage.

Opioid-Induced Hyperalgesia: When the Treatment Worsens the Problem

Perhaps the most counterintuitive finding in chronic pain research: long-term opioid use can paradoxically increase pain sensitivity—a phenomenon called opioid-induced hyperalgesia (OIH). Chronic opioid exposure triggers compensatory neuroplastic changes that amplify pain signaling as the nervous system attempts to counterbalance opioid suppression.

Mechanisms include activation of NMDA receptors by morphine metabolites, downregulation of descending pain inhibition pathways, and microglial activation driven by opioid signaling. The clinical result: patients on escalating opioid doses report increasing pain despite the medication, and dose reduction paradoxically reduces pain intensity in some patients.

• OIH is distinct from opioid tolerance—tolerance is reduced drug effect, OIH is increased pain sensitivity
• Studies suggest OIH can develop within weeks of regular opioid use at therapeutic doses
• Methadone at low doses may be protective against OIH due to its NMDA receptor antagonism

Evidence-Based Treatment Beyond Opioids

Pain neuroscience education—teaching patients about central sensitization mechanisms—has been shown in multiple RCTs to reduce pain catastrophizing, disability, and healthcare utilization even before any other treatment is applied. Understanding that chronic pain reflects nervous system adaptation rather than ongoing tissue damage changes the psychological relationship with the symptom and reduces fear-avoidance behavior that perpetuates disability.

This article is for informational purposes only. Consult a qualified professional for medical guidance on pain management.